TITLE

What Have We Learned From the Biological Therapies in Ulcerative Colitis?

AUTHOR(S)
Peña, Amado Salvador
PUB. DATE
June 2001
SOURCE
American Journal of Gastroenterology;Jun2001, Vol. 96 Issue 6, p1681
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the efficacy and tolerability of interferon alfa-2a in patients with active left-sided ulcerative colitis. Prognosis of ulcerative colitis; Clinical studies on interferon alfa-2a; Factors limiting the applications of interferon alfa-2a.
ACCESSION #
17636121

 

Related Articles

  • Interfering with interferons in inflammatory bowel disease. Ghosh, S.; Chaudhary, R.; Carpani, M.; Playford, R. // Gut;Aug2006, Vol. 55 Issue 8, p1071 

    The article discusses the use of interferons for the treatment of inflammatory bowel disease. Interferons show antitumor and antiviral activities. In inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, there is an increase in plasma and tissue concentrations of...

  • Evolving knowledge and therapy of inflammatory bowel disease. Korzenik, Joshua R.; Podolsky, Daniel K. // Nature Reviews Drug Discovery;Mar2006, Vol. 5 Issue 3, p197 

    With recent advances in the understanding of its pathophysiology, inflammatory bowel disease has become a very active area for the development of novel therapeutic agents. New targets for biologics include cytokines involved in T-cell activation, with antibodies directed against IL-12 and...

  • Remicade adds UC to list of indications.  // Drug Topics;9/26/2005, Vol. 149 Issue 18, p8 

    This article reports that Centocor Inc.'s anti-tumor necrosis factor alpha therapy, Remicade, has been approved for the treatment of ulcerative colitis, making it the first and only biologic approved for this indication.

  • Decreased Incorporation of 14C-Glucosamine Relative to 3H-N-Acetyl Glucosamine in the Intestinal Mucosa of Patients with Inflammatory Bowel Disease. Burton, A. F.; Anderson, F. H. // American Journal of Gastroenterology;Jan1983, Vol. 78 Issue 1, p19 

    The synthesis of glycoproteins was investigated in intestinal mucosa from patients with inflammatory bowel disease (IBD) and from those with various other conditions. The incorporation into acid-insoluble macromolecules of the amino sugar glucosamine, the first and committed metabolite in the...

  • Successful twin pregnancy in a patient with ulcerative colitis using azathoprine during conception. Casella, Giovanni; Villanacci, Vincenzo; Antonelli, Elisabetta; Di Bella, Camillo; Baldini, Vittorio; Nejad, Mohammad Rostami; Bassotti, Gabrio // Gastroenterology & Hepatology from Bed to Bench;Oct2011, Vol. 4 Issue 4, p224 

    Inflammatory bowel disease (IBD) frequently affects young patients of childbearing age. Treatments for inflammatory bowel disease include immunosuppressive, cytotoxic and surgical therapies. Azathioprine is frequently used to treat patients with steroid dependent IBD. We report the case of a...

  • Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Balzola, Federico; Cullen, Garret; Ho, Gwo-Tzer; Russell, Richard K. // Inflammatory Bowel Disease Monitor;2013, Vol. 14 Issue 1, p21 

    The article presents a study that examines the safety of thiopurine medications in patients with inflammatory bowel diseases (IBD). It offers overview of the method of the study that observes 4000 patients with IBD and the long-term adverse events of thiopurine. It notes the result of the study...

  • Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity.  // Inflammatory Bowel Disease Monitor;2010, Vol. 11 Issue 2, p82 

    The article discusses a study which investigates the role of topical rosiglitazone treatment in improving ulcerative colitis (UC) through the restoration of peroxisome proliferator-activated receptor-γ (PPARγ) activity. It notes that through inhibiting the activator protein-1, nuclear...

  • Update of the management of inflammatory bowel disease.  // Archives of Disease in Childhood;Jan2012, Vol. 97 Issue 1, p78 

    Up to 25% of patients with Crohn's disease and ulcerative colitis present before the age of 18 years. Although the pathophysiology of inflammatory bowel disease presenting in childhood does not differ fundamentally from that presenting in adulthood, managing these younger patients requires...

  • Recent Indications and Methods of Surgery for Inflammatory Bowel Disease. S. Ohki; S. Terashima; K. Sekikawa; S. Takenoshita; M. Gotoh // Current Drug Targets - Inflammation & Allergy;Jun2003, Vol. 2 Issue 2, p113 

    Inflammatory bowel disease, notably ulcerative colitis (UC) or Crohn disease (CD), is basically benign, but sometimes develops into serious or fatal cancer. While the primary therapies are medical, such as pharmacotherapy and dietetic modification, intractable, serious, and cancerous cases can...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics